glp-1 and parkinson's disease A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes obesity, including cardiovascular and neurodegenerative disorders PDF] Novel dual GLP-1/GIP receptor

Small studies suggest possible benefits for irritability or hyperactivity, but rigorous randomized controlled trials are lacking

Fatigue and energy changes Some people experience fatigue on GLP-1 medications , especially during the first few weeks

105 Extreme temperatures and inadequate hydration further contribute to dysregulated GI function

Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum

Pairing daily protein targets with regular strength training is the best-supported combination for preserving lean mass in a deficit

CP-25 can improve the ankle pannus formation in AA rats (144), and its possible mechanism is that it inhibits the plasma membrane localization of G protein-coupled receptor kinase 2 (GRK2) in human umbilical vein endothelial cells (HUVECs) and down-regulates the GRK2-induced endothelial C-X-C chemokine receptor type 4 (CXCR4)-ERK1/2 signaling pathway to exert anti-angiogenic effects